

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/717,738	11/20/2003	Hiroyuki Odaka	087147-0604	8700
22428 EOLEV AND	7590 07/18/2007		EXAM	INER
FOLEY AND LARDNER LLP SUITE 500			WEDDINGTON, KEVIN E	
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
		•	1614	
	•		· · · ·	
		·.	MAIL DATE	DELIVERY MODE
			07/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/717,738	ODAKA ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Kevin E. Weddington	!				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING Down a series of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMN 36(a). In no event, however, will apply and will expire SIX (b. cause the application to bec	MUNICATION. may a reply be timely filed by MONTHS from the mailing date of this communication. come ABANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 01 M	lay 2007.					
,-						
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	Ex parte Quayle, 193	5 C.D. 11, 453 O.G. 213.				
Disposition of Claims		•				
4) Claim(s) 9,16,18 and 24 is/are pending in the	application.					
4a) Of the above claim(s) is/are withdra	wn from consideratio	n.				
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>9, 16, 18 and 24</u> is/are rejected.						
	7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requireme	nt.				
Application Papers						
9) The specification is objected to by the Examine	er.					
· / <u></u> · · ·	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the E	xaminer. Note the att	ached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12)☐ Acknowledgment is made of a claim for foreign	n priority under 35 U.	S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
Certified copies of the priority document	ts have been receive	d in Application No				
Copies of the certified copies of the price						
application from the International Burea	•					
* See the attached detailed Office action for a list of the certified copies not received.						
	•					
Attachment(s)	•.	·				
1) Notice of References Cited (PTO-892)		erview Summary (PTO-413) per No(s)/Mail Date				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Not	ice of Informal Patent Application				
Paper No(s)/Mail Date	6) 🔲 Oth	er:				

Art Unit: 1614

Claims 9, 16, 18 and 24 are presented for examination.

Applicants' amendment and response filed May 1, 2007 have been received and entered.

Accordingly, the rejection made under 35 USC 112, first paragraph as set forth in the previous Office action dated January 5, 2007 at pages 3-6 is withdrawn by the amendment to the claims to recite only "metformin".

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 9, 16, 19 and 24 are again rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 8, 10, 11, 14 and 15 of U.S. Patent No. 6,677,363. Although the conflicting claims are not

Application/Control Number: 10/717,738

Art Unit: 1614

identical, they are not patentably distinct from each other because of reasons set forth in the previous Office action dated January 5, 2007 is MAINTAINED.

Applicants' remarks regarding the obviousness-type double patenting (ODP) rejection is improper and should be withdrawn under 35 USC 121 are not persuasive since the cited reference (Medical Dictionary: Ketosis) states the definition of "ketosis" and "acidosis" are synonymous and interchangeable. Clearly, one skilled in the art would assume the terms "ketosis" and "acidosis" are the same unless one can prove the terms are "separate and different" in the absence of evidence to the contrary.

The rejection made under obviousness-type double patenting is adhered to. Claims 9, 16, 18 and 24 are not allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/717,738 Page 4

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571) 272-0587. The examiner can normally be reached on 12:30 pm-9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington July 13, 2007